The company has partnered with Andrus for the distribution of Binosto in Russia, Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Ukraine and Uzbekistan.
Through another partnership, with Adcock Ingram Heathcare, Binosto will be available in South Africa, Namibia, Botswana, Swaziland, Lesotho, Zimbabwe, Kenya and Ghana.
Binosto, the first commercial product of EffRx, is a buffered, effervescent formulation of alendronate and the most broadly prescribed treatment for osteoporosis.
The product has been approved by the US Food and Drug Administration in 2012.
EffRx chief commercial officer Lorenzo Bosisio said the company is happy to expand the global footprint of Binosto with the addition of these fast-growing emerging markets.
"Binosto is our first approved product and provides an important proof of concept for our development pipeline of novel therapeutic entities, and we look forward to making it available to an increasing population with these two agreements."
EffRx chairman and chief executive officer Christer Rosén said the continued worldwide adoption of Binosto is the first of the company’s current out-licensing initiatives and is expected to provide a steady income stream in the future.
"We continue to focus on the two other, potentially larger, elements of our threefold growth strategy – products in the orphan drug segment, including the ongoing development of our PCOS product, and lifecycle management," Rosén said.